Treatment options for invasive fungal infections

Pharmacotherapy

Volumn 26, Issue 6 II, 2006, Pages

  Dodds Ashley, Elizabeth S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Campbell University   (United States)

Author keywords

Amphotericin B; Antifungal therapy; Azoles; Drug interactions; Echinocandins

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TACROLIMUS; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCES; CANDIDA; CANDIDIASIS; CHILL; CLINICAL TRIAL; COCCIDIOIDES; CONFERENCE PAPER; CRYPTOCOCCUS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEVER; FUNGEMIA; FUSARIUM; HISTOPLASMA; HUMAN; MYCOSIS; NEPHROTOXICITY; RARE DISEASE; SCEDOSPORIUM; VOMITING; ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; DRUG INTERACTIONS; FUNGAL PROTEINS; FUNGEMIA; HUMANS; PEPTIDES, CYCLIC;

EID: 33744497566     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.6part2.55S     Document Type: Conference Paper

References (18)

1. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003;37:415-25.
2. Branch RA. Prevention of amphotericin B-induced renal impairment: review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
3. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:1-6.
4. Mora-Duarte J, Betts R, Rotstein C, et al, for the Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;3437:2020-9.
5. Zaas AK, Dodds Ashley ES, Alexander BD, Johnson J, Perfect JR. Caspofungin for invasive candidiasis: experience at DUMC 2001-2004. Presented at the 44th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, October 30-November 2, 2004.
6. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
7. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-9.
8. Reboli A, Pappas P, Schranz J, Krause D, Walsh T, for the Anidulafungin 1C Study Group. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis. Presented at the 45th interscience conference on antimicrobial agents and chemotherapy Washington, DC, December 16-19, 2005.
9. Herbrecht R, Denning DW, Patterson TF, et al, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
10. Ally R, Schürmann D, Kreisel W. et al, and the Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54.
11. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31.
12. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42.
13. Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI) [abstr]. In: Program and abstracts of the 44th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, October 30-November 2, 2004. Washington, DC: American Society for Microbiology, 2004:M-669.
14. Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004;53:113-14.
15. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
16. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-9.
17. Marr KA, Hachem R, Papanicolaou G, et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transplant Infect Dis 2004;6:110-18.
18. Astellas Pharma US Inc. Mycamine (micafungin) package insert. Deerfield, IL; April 2005.